Stempeutics Plans To Launch Stem Cell Device In India By Mid 2016

An innovative stem cell medical device 'Stempeutron' by the stem cell company Stempeutics Research will be launched in India by the middle of next year subject to regulatory approvals.

The device, which can obtain a population of cells collectively known as the stromal vascular fraction (SVF) from fat tissues, to be used for later treatment of osteoarthritis and diabetic foot ulcer to even breast augmentation surgery, is estimated to be priced at USD 50,000.

Scientists Use Stem Cells To Grow Miniature Human Kidney In a Dish
Scientists grew kidney-like structure using induced pluripotent stem (iPS) cells, which is a complicated task as organs are composed of a multitude of different cell types.

"We plan to launch our novel device Stempeutron in India by middle of next year as soon as we get regulatory nod for it. It will be launched in multiple hospitals across the country before it goes global," said Stempeutics MD and CEO B N Manohar.

The company is looking for a strategic partner to globalize and market this device in India and outside.

The device will be launched first in India, followed by South East Asia and then Europe and US, he said, adding the estimated selling price of the consumables would be USD 1,000.

Embryonic Stem Cells Could Help Study Pollution Effects on Human Health
Stem cell toxicology system proved to be very sensitive and reflective of the physiological toxic effects of the environmental pollutant Bisphenol A.

"We have already received go ahead from Cipla to either sell the product or to enter into a partnership with a big player to commercialize the device," said Manohar.

"As a country we are usually importer of medical devices. The development of this device is a big achievement for Stempeutics as it is first device to be developed indigenously based on a novel process and technology," said Manohar.

Copenhagen Researchers Find How Stem Cells Generate Insulin-producing Cells in Labs
Stem cells combine specific sets of proteins at precise positions along the DNA. When these particular groups of proteins combine, they get a new identity.

There is USD 30 billion treatment opportunity globally for SVF applications, which is multi potent therapy that has potential to meet significant medical needs.

The Bengaluru-based Stempeutics Research was founded by Manipal Education and Medical Group (MEMG) in 2006 and later entered into a strategic alliance with Cipla in 2009 and is now a JV firm. It develops stem cell based medicinal products, with facilities in Bangalore and Manipal as well as at Kuala Lumpur in Malaysia.

Stem Cells Programmed With MiR-133, a New Alternative Therapy For the Damaged Heart
Infusing a special molecule miR-133a along with mesenchymal stem cells produced microRNA’s which survived and healed scarred tissue in the heart.

Source-PTI